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Propositions 
Stellingen behorende bij het proefschrift 
Title: TNF receptor superfamily-based targeted cancer immunotherapy 
 
1. Tumor-selective agonistic TRAIL-R2 antibodies are excellent candidates for further clinical 
development for the treatment of malignant melanoma and possibly other malignancies. 
(This thesis) 
2. The multifunctionality of TRAIL fusion proteins can be exploited not only to selectively target 
and eliminate cancer cells, but also to modulate anticancer immune responses. (This thesis) 
3. Pre-targeting of TNFSF ligands is a promising strategy for enhancing the therapeutic 
applicability of these ligands given the possibility to remotely control antitumor activity 
and/or unwanted toxicity. (This thesis) 
4. Tumor-directed ‘second-generation’ TRAIL receptor agonists have superior anticancer 
activity and probably less side effects compared to untargeted ‘first-generation’ agonists. 
(This thesis) 
5. “Cancer continues to adapt and evolve to perpetuate itself. We need to adapt and evolve 
even faster”. From ‘The death of Cancer’, 2015 by Vincent T. Devita Jr. and  Elizabeth DeVita-
Raeburn. 
6. “Only two things are infinite, the universe and human stupidity, and I'm not sure about the 
universe.” Albert Einstein. 
7. 不择手段非豪杰，不改初衷真英雄----《道士下山》”Some will do anything to succeed, 
but a hero will stay true to himself”. From the 2014 motion picture: ‘Monk comes down the 
mountain’ . 
8. 路漫漫其修远兮，吾将上下而求索-----屈原《楚辞》 “The way ahead is long, I see no ending, 
yet high and low, I’ll search with my will unbending”. Qu yuan  (Verses of Chu), BC340-278. 
9. 一语不能践，万卷徒空虚----明.林鸿《饮酒》 “Only talking cannot generate knowledge but 
practicing can”. Lin Hong, poet Ming dynasty, AD 1374. 
 
 
